TRANCOPAL
LOE ApproachingNDAORALTABLET
Approved
May 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRANCOPAL is an oral small-molecule tablet approved by the FDA in 1960 as a New Drug Application (NDA) sponsored by Sanofi. The mechanism of action, pharmacologic class, and specific indications are not publicly detailed in available data. This is a legacy product with a long market history dating back over 60 years.
LOE Approaching
As LOE approaches, this product faces commercial headwinds with moderate competitive pressure (30% intensity); career roles will shift toward defensive strategies and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRANCOPAL offers limited career growth opportunities given its LOE approaching status and zero linked job postings. Roles on this product focus on defending market share and managing decline rather than building new capabilities or scaling teams.
Brand ManagerField Sales Representative
Worked on TRANCOPAL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.